Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15

Evercore ISI Group analyst Cory Kasimov has downgraded Upstream Bio (NASDAQ: UPB) from Outperform to In-Line. The price target for the stock has been significantly reduced from $40 to $15.